Calcification propensity diagnostics start-up Calciscon raises CHF 2.5 million

Bernese medtech start-up Calciscon, the developer of the first and only diagnostic blood test for the assessment of the formation of crystalline phosphate particles in blood, has announced the closing of a Series A funding round in the amount of CHF 2.5 million.

Founded in 2013 as a result of breakthrough research in renal medicine by Andreas Pasch who investigated why the blood vessels of kidney patients calcify rapidly, start-up Calciscon has developed the T50 Calcification Propensity test (T50 test), the first functional test to assess the speed of calcification in the body.

The CE-marked T50 blood test identifies patients with high cardiovascular risk and opens the possibility to guide therapies to slow down disease progression. This information helps doctors better guide therapies of kidney disease patients.

Multiple studies indicate that T50-guided therapies slow down calcification propensity, and could significantly reduce cardiovascular complications, which remains the most common cause of morbidity and mortality among renal patients.

“The T50 creates an unprecedented opportunity to reduce the extensive harm and healthcare costs associated with CV complications”, explains Andreas Pasch, inventor of the T50 test and founder of Calciscon.

The company has recently closed a CHF 2.5 million series A financing round, which will allow it to accelerate the introduction of its T50 test in routine clinical use in Europe, and prepare for a US launch. The round was raised from a group of investors led by Switzerland-based Yellowstone Holding.

Based in Nidau in the canton of Bern, Calciscon has so far raised a total of CHF 5 million cumulated equity investment.